⟶ Updated 10 months ago ⟶
List of edits
Rochester physicians Dr. Burtis Breese and Dr. Frank Disney partner to form a private group practice which was very unusual at the time since most physicians practiced alone.
Doctors Breese and Disney undertake office-based research to improve the diagnostic process for strep throat. The men fashion an office incubator to grow bacteria from patient throat swabs. Their work is published and the two start to gain notoriety for their efforts.
After looking at how to diagnose strep, Doctors Breese and Disney start to work on how to treat the condition. They start to test penicillin for dosing and effectiveness. Before long they are testing every antibiotic indicated for strep throat, many of which are still used today.
The University of Rochester Medical Center (URMC) forms its Vaccine Research Unit to design and conduct studies looking at how to prevent disease that includes influenza, avian flu, pneumococcal disease, anthrax, herpes, malaria, human papillomavirus (HPV), and smallpox.
David Smith, MD, a URMC researcher, leads the team that successfully creates the first vaccine for Haemophilus influenzae type B (Hib), a cause of meningitis. Pediatric patients in Rochester are able to receive the vaccine several years ahead of children living elsewhere.
Janet Casey, MD, a Duke-trained pediatric hematologist with interest in studying infectious disease in an immunocompromised host, relocates to Rochester. She decides to leave the hematology field and joins a general pediatrics practice.
The pediatric pneumococcal conjugate vaccine called Prevnar is introduced. The vaccine provides immunity to seven strains of bacteria streptococcus pneumoniae. Its “conjugate” platform, which makes the vaccine more effective in infants, was developed at URMC.
Dr. Casey and her team receive a grant from the National Institutes of Health to study the immunologic basis of ear infections and the changing microbiology due to the Prevnar vaccine. This forms the basis for the “ear immunity” study that gains national exposure for Legacy Pediatrics.
The six-year ear immunity trial wraps up with Legacy performing over 400 successful ear taps to determine the specific bacteria causing an infection to inform optimal antibiotic selection. More than 8,000 nasal washes, nasal cultures, throat cultures and blood samples were performed. Study results show that personalized care reduces the frequency of infections and the need for ear tubes.
Legacy partners with leading medical research entity, Rochester Clinical Research. Legacy participates in a trial looking at the efficacy of laboratory testing for the Ebola virus. In September the practice starts enrolling infants in a vaccine trial against invasive meningococcal disease. Currently children are not vaccinated against the condition until they are ten years old.
About & Feedback